FDA To Consider Approving Ecstasy To Treat PTSD

May 7, 2024 Medicine, Science

The Food and Drug Administration’s panel of independent advisers will on June 4 deliberate whether they should recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder, Lykos Therapeutics said on Monday.

This would be the first FDA panel of outside experts to review a potential new PTSD treatment in 25 years.

In support of its application, Lykos Therapeutics, formerly known as Multidisciplinary Association for Psychedelic Studies (MAPS), studied the party drug MDMA, more commonly called ecstacy or molly, in two late-stage studies.

Read the full article.

The FDA’s panel of independent advisers will on June 4 decide whether to recommend approval for the first MDMA-assisted therapy for PTSD. No psychedelic-based therapy has been approved yet in the U.S. https://t.co/rqw0USJf0o

— NBC News (@NBCNews) May 7, 2024